Skip to main content
By kristalamb
Posted date: January 17, 2022

In December, Diabetes Action Canada member Dr. Bruce Perkins and his collaborators were awarded a Diabetes Canada End Diabetes: 100 Award.

Their project, which will incorporate Patient Partners at all levels, looks at ways to reduce and prevent diabetic ketoacidosis (DKA) in type 1 diabetes. The research team will work to identify factors that may increase the risk of DKA, define ways that people with diabetes can mitigate DKA and then create an educational tool to help increase awareness around factors that can reduce risk. The team will then test the tool to ensure it is effective and helpful.

Because DKA is a common and potentially deadly complication in type 1 diabetes, this project is particularly important to those living with diabetes and to their caregivers and health care providers. For Perkins, it also offers the opportunity to continue his work looking at the potential for using a newer form of drug therapy called sodium glucose transport inhibitors (SGLTis) in those with type 1 diabetes. Currently, the therapy is being used with much success in those with type 2 diabetes, but the risk of DKA has meant it is not available for those with type 1 in North America.

“Despite improvements in monitoring and treatment over the last 100 years, DKA continues to be an ongoing and very frightening issue for people living with type 1 diabetes,” says Perkins. “This means that new therapies and medications, like SGLTis, which have shown the potential for positive outcomes are not currently available for those with type 1. Our study will look at ways to help everyone with diabetes reduce the risk of developing DKA and potentially open the door for new drug therapies in the future.”

In addition to the Perkins lab, a Diabetes Action Patient Partner, Doug Mumford, will be a co-lead on the project. Diabetes Action Canada researcher, Dr. Noah Ivers, will also be a collaborator, helping to support the development of the educational tool and its implementation. It is anticipated that a large number of patient co-researchers will be involved throughout the project to ensure the outcome meets the needs of the type 1 diabetes community.

Featured in Article

Bruce Perkins


Associated Programs

Innovations in Type 1 Diabetes

Creating collaborative patient-oriented research programs that enables innovative research in T1D.

Related Podcasts

Closed Loop Technolgies and the DIY Community

Episode three features an interview with Patient Partner Kate Farnsworth and Dr. Bruce Perkins about closed loop technologies and the DIY looping community.

Related Articles

Adjunct Therapies in Type 1 Diabetes

[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget] To date there are no licensed therapies for Type 1 diabetes except insulin in Canada. Recently the European Medicines Agency has given approval for Dapaglifozin in T1D, while the FDA rejected Sotagliflozin. Trials of these agents in Type 1 have shown modest reductions in HbA1c, weight and insulin use, with an increase in […]

Diabetes Action Canada Research Published in Nature Medicine

Exciting new research from the Drs. Bruce Perkins and Ahmad Haidar labs has been published in Nature Medicine. This project looks at how a combination therapy could have the potential to improve blood sugar control and the performance of an artificial pancreas. The paper, “Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: […]


Tracy McQuire Promoted to Executive Director for Diabetes Action Canada

Tracy McQuire Promoted to Executive Director for Diabetes Action Canada

Social Media for Scientists Webinar